VREOF Vireo Growth Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1771706 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY255.9%
TTM net income YoY-2.2%
TTM EPS YoY149.6%
Revenue 3-yr CAGR101.0%
Net income 3-yr CAGR—
Margins
Gross margin47.4%
Operating margin1.3%
Net margin-9.6%
FCF margin-14.6%
EBITDA margin5.4%
Returns
ROE-17.5%
ROA-6.2%
ROIC (approx.)3.3%
Asset turnover0.64x
Leverage & solvency
Liabilities / assets65.3%
Debt / equity0.00x
Current ratio1.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.58x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue20.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $268.77M | $99.38M | $88.13M | $74.63M | $54.45M |
| Cost of revenue | — | — | — | $39.42M | $32.01M |
| Gross profit | $127.10M | $50.77M | $44.10M | $30.91M | $19.80M |
| SG&A expense | $81.19M | $28.06M | $28.22M | $33.82M | $33.66M |
| Operating income | -$1.05M | $13.56M | $10.58M | -$6.94M | -$20.48M |
| Interest expense | — | $31.19M | $31.26M | $22.59M | $10.58M |
| Pretax income | -$39.91M | -$16.89M | -$17.82M | -$36.56M | -$29.57M |
| Income tax | $28.23M | $11.11M | $7.72M | $5.89M | $4.12M |
| Net income | -$68.11M | -$28.01M | -$25.55M | -$42.46M | -$33.69M |
| EBITDA | $15.06M | $16.10M | $13.45M | -$3.60M | -$17.45M |
| EPS (basic) | -0.09 | -0.16 | -0.19 | -0.33 | -0.27 |
| EPS (diluted) | -0.09 | -0.16 | -0.19 | -0.33 | -0.27 |
| Weighted avg. shares (diluted) | 734.74M | 180.39M | 135.24M | 128.13M | 123.81M |
| Banking | |||||
| Loans, net | — | — | $3.75M | $3.75M | — |
| Balance sheet | |||||
| Cash & equivalents | $122.50M | $91.60M | $15.96M | $15.15M | $15.16M |
| Short-term investments | $1.00M | — | — | — | — |
| Receivables | $12.70M | $2.87M | $2.26M | $4.29M | $4.50M |
| Inventory | $60.00M | $21.67M | $19.29M | $20.51M | $20.42M |
| Current assets | $305.10M | $230.37M | $148.85M | $46.73M | $41.64M |
| PP&E, net | $217.50M | $32.31M | $23.29M | $89.61M | $99.49M |
| Goodwill | $87.50M | $0 | $0 | $183,836 | $183,836 |
| Intangibles | $117.50M | $7.90M | $8.72M | $8.78M | $10.18M |
| Total assets | $817.20M | $278.86M | $183.26M | $159.16M | $166.97M |
| Current liabilities | $191.70M | $135.47M | $179.47M | $29.71M | $16.41M |
| Short-term debt | — | — | — | $11.78M | — |
| Long-term debt | — | — | — | $46.25M | $27.33M |
| Total debt | — | — | — | $58.03M | $27.33M |
| Total liabilities | $509.80M | $223.30M | $199.31M | $155.72M | $123.96M |
| Shareholders' equity | $307.40M | $55.50M | -$16.04M | $3.44M | $43.01M |
| Net debt | — | — | — | $42.88M | $12.17M |
| Cash flow statement | |||||
| Operating cash flow | $3.71M | -$10.23M | -$965,906 | -$18.07M | -$30.52M |
| Capital expenditure | $28.32M | $11.69M | $4.96M | $5.56M | $18.04M |
| Free cash flow | -$24.61M | -$21.93M | -$5.93M | -$23.63M | -$48.56M |
| Investing cash flow | $8.76M | -$8.13M | -$3.48M | -$5.62M | -$7.21M |
| Financing cash flow | $18.42M | $94.01M | $5.26M | $23.68M | $25.78M |
| Depreciation & amortization | $16.11M | $2.54M | $2.87M | $3.34M | $3.03M |
| Stock-based compensation | $18.66M | $3.63M | $4.16M | $2.69M | $5.18M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.